Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG
Raymond A. Alvarez, … , Viviana Simon, Benjamin K. Chen
Raymond A. Alvarez, … , Viviana Simon, Benjamin K. Chen
Published February 23, 2017
Citation Information: JCI Insight. 2017;2(4):e88226. https://doi.org/10.1172/jci.insight.88226.
View: Text | PDF
Research Article AIDS/HIV Infectious disease

Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG

  • Text
  • PDF
Abstract

HIV-1 viremic controllers (VC) spontaneously control infection without antiretroviral treatment. Several studies indicate that IgG Abs from VCs induce enhanced responses from immune effector cells. Since signaling through Fc-γ receptors (FCGRs) modulate these Ab-driven responses, here we examine if enhanced FCGR activation is a common feature of IgG from VCs. Using an infected cell–based system, we observed that VC IgG stimulated greater FCGR2A and FCGR3A activation as compared with noncontrollers, independent of the magnitude of HIV-specific Ab binding or virus neutralization activities. Multivariate regression analysis showed that enhanced FCGR signaling was a significant predictor of VC status as compared with chronically infected patients (CIP) on highly active antiretroviral therapy (HAART). Unsupervised hierarchical clustering of patient IgG functions primarily grouped VC IgG profiles by enhanced FCGR2A, FCGR3A, or dual signaling activity. Our findings demonstrate that enhanced FCGR signaling is a common and significant predictive feature of VC IgG, with VCs displaying a distinct spectrum of FCGR activation profiles. Thus, profiling FCGR activation may provide a useful method for screening and distinguishing protective anti-HIV IgG responses in HIV-infected patients and in monitoring HIV vaccination regimens.

Authors

Raymond A. Alvarez, Ana M. Maestre, Kenneth Law, Natasha D. Durham, Maria Ines Barria, Akiko Ishii-Watabe, Minoru Tada, Manav Kapoor, Mathew T. Hotta, Gabriela Rodriguez-Caprio, Daniel S. Fierer, Ana Fernandez-Sesma, Viviana Simon, Benjamin K. Chen

×

Figure 3

FCGR2A signaling in response to HIV+ patient IgG Abs.

Options: View larger image (or click on image) Download as PowerPoint
FCGR2A signaling in response to HIV+ patient IgG Abs.
Graphs depict the ...
Graphs depict the levels of FCGR2A signaling mediated by HIV+ patient IgG opsonized HIV-1 Δvpu–infected target cells. For FCGR signaling experiments, Abs were diluted 10-fold, starting at a top concentration of 250 μg/ml in a 5-point titration curve. (A and C) Maximum signals achieved at the top concentration of Abs tested (250 μg/ml). (B and D) The area under the signaling curve. (A and B) Comparison of VC vs. CIP. (C and D) Comparison of LTNPs, ECs, and CIPs. The mean of 3 experiments for n = 50 IgG is shown.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts